Ketosol 100 mg/ml Solution for Injection for Horses, Cattle and Pigs

Main information

  • Trade name:
  • Ketosol 100 mg/ml Solution for Injection for Horses, Cattle and Pigs
  • Pharmaceutical form:
  • Solution for injection
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Ketosol 100 mg/ml Solution for Injection for Horses, Cattle and Pigs
    Italy
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • ketoprofen
  • Therapeutic area:
  • Cattle, Horses, Pigs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0382/001
  • Authorization date:
  • 25-04-2012
  • EU code:
  • UK/V/0382/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:October2012

AN:00043/2011

Page1of6

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Ketosol100mg/mlsolutionforinjectionforhorses,cattleandpigs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Perml:

Activesubstance:

Ketoprofen 100mg

Excipients:

Benzylalcohol(E1519) 10mg

Forfulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Solutionforinjection.

Clear,lightyellowsolution.

4. CLINICALPARTICULARS

4.1 Targetspecies

Horses,cattle,pigs.

4.2 Indicationsforuse,specifyingthetargetspecies

Horses:

- thealleviationofinflammationandpainassociatedwithmusculoskeletal

disorders

- thealleviationofvisceralpainassociatedwithcolic.

Cattle:

- thesupportivetreatmentofparturientparesisassociatedwithcalving

- reducingthepyrexiaanddistressassociatedwithbacterialrespiratorydisease

whenusedinconjunctionwithanantimicrobialtherapyasappropriate

- improvingtherecoveryrateinacuteclinicalmastitis,includingacuteendotoxin

mastitis,causedbygramnegativemicroorganisms,inconjunctionwith

antimicrobialtherapy

- reducingoedemaoftheudderassociatedwithcalving.

Issued:October2012

AN:00043/2011

Page2of6

Pigs:

- reducingthepyrexiaandrespiratoryrateassociatedwithbacterialorviral

respiratorydiseasewhenusedinconjunctionwithantimicrobialtherapyas

appropriate

- thesupportivetreatmentofMastitisMetritisAgalactiaSyndromeinsows,in

conjunctionwithantimicrobialtherapyasappropriate.

4.3 Contraindications

Donotuseinhorses,cattleorpigsthathavepreviouslyshownahypersensitivityto

ketoprofen.

Donotadministerothernon-steroidalanti-inflammatorydrugs(NSAIDs)concurrently

orwithin24hoursofeachother.

Donotuseinanimalssufferingfromcardiac,hepaticorrenaldisease,wherethereis

thepossibilityofgastrointestinalulcerationorbleeding,wherethereisevidenceofa

blooddyscrasiaorhypersensitivitytothemedicinalproduct.

4.4 Specialwarningsforeachtargetspecies

None

4.5 Specialprecautionsforuse

Specialprecautionsforuseinanimals

Useinanyanimallessthan6weeksofageorinagedanimalsmayinvolve

additionalrisk.Ifsuchusecannotbeavoidedanimalsmayrequireareduceddosage

andcarefulmanagement.

Donotuseinfoalsundertheageof15days.

Avoiduseinanydehydrated,hypovolemicorhypotensiveanimalsasthereisa

potentialriskofincreasedrenaltoxicity.

Avoidintra-arterialinjection.

Donotexceedthestateddoseordurationoftreatment.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttotheanimals

Incaseofaccidentalself-injectionseekmedicaladviceandshowthepackageleaflet

orthelabeltothephysician.

Peoplewithknownhypersensitivitytotheactivesubstanceand/orbenzylalcohol

shouldavoidcontactwiththeproduct.

Avoidsplashesontheskinandeyes.Washtheaffectedareathoroughlywithwater

shouldthisoccur.Ifirritationpersistsseekmedicaladvice.

Washhandsafteruse.

Issued:October2012

AN:00043/2011

Page3of6

4.6 Adversereactions(frequencyandseriousness)

IncommonwithallNSAIDs,duetotheiractionofinhibitionofprostaglandin

synthesis,therecanbeapossibilityincertainindividualsofgastricorrenal

intolerance.

Allergicreactionsmayoccurveryrarely,inthiscasethetreatmentshouldbe

stopped.

Followingintramuscularinjection,localirritationattheinjectionsitecanbeseen.

4.7 Useduringpregnancy,lactationorlay

Thesafetyofketoprofenhasbeeninvestigatedinpregnantanimals(rats,rabbits)

andcattle.Ketoprofenshowednoteratogenicorembryotoxiceffects.However,in

theabsenceofspecificdatainpregnantmaresandsows,theuseoftheproductin

theseanimalsshouldbesubjecttoabenefit/riskassessmentbytheresponsible

veterinarian.

Itisindicatedforuseinlactatingsows.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

SomeNSAIDsmaybehighlyboundtoplasmaproteinsandcompetewithother

highlybounddrugswhichcanleadtotoxiceffects.

Concurrentadministrationwithnephrotoxicdrugsshouldbeavoided.

Concurrentadministrationofothersteroidalornon-steroidalanti-inflammatorydrugs,

diureticsoranticoagulantagentsmayleadtopotentiatingadverseeffects.A

treatmentfreeperiod,dependentontheproductadministered,shouldbeobserved

betweensuchtreatments.

4.9 Amountstobeadministeredandadministrationroute

Horse:intravenoususe

Foruseinmusculoskeletalconditions,therecommendeddosageis2.2mg

ketoprofen/kgofbodyweight,i.e.1mloftheproduct/45kgofbodyweight,

administeredbyintravenousinjectiononcedailyforupto3to5days.

Foruseinequinecolic,therecommendeddosageis2.2mgketoprofen/kgofbody

weight,i.e.1mloftheproduct/45kgofbodyweight,givenbyintravenousinjection

forimmediateeffect.

Onlyafterathoroughre-examinationasecondinjectionmaybegivenifcolicrecurs.

Cattle:intravenoususe,intramuscularuse

Therecommendeddosageis3mgketoprofen/kgofbodyweight,i.e.1mlofthe

product/33kgofbodyweight,administeredbyintravenousordeepintramuscular

injectiononcedailyforupto3days.

Pig:intramuscularuse

Therecommendeddosageis3mgketoprofen/kgofbodyweight,i.e.1mlofthe

product/33kgofbodyweight,administeredoncebydeepintramuscularinjection.

Donotadministermorethan10mlateachinjectionsite.

Thestoppercannotbepuncturedmorethan20times.

Issued:October2012

AN:00043/2011

Page4of6

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Noclinicalsignswereobservedwhenketoprofenwasadministeredtohorsesat5

timestherecommendeddosefor15days,tocattleat5timestherecommended

dosefor5days,ortopigsat3timestherecommendeddosefor3days.

4.11Withdrawalperiod(s)

Horses,cattleandpigsmustnotbeslaughteredforhumanconsumptionduring

treatment.Animalsmaybeslaughteredforhumanconsumptiononlyafterthe

followingperiodsfromthelasttreatment:

Cattle

meatandoffal:followingintravenousadministration-1day

followingintramuscularadministration-4days

milk:zerohours

Pigs(meatandoffal):4days

Horses(meatandoffal):1day

Nottobeusedinmaresproducingmilkforhumanconsumption.

5. PHARMACOLOGICALPROPERTIES

ATCVetcode:QM01AE03

Group:Antiinflammatoryandantirheumaticproducts,nonsteroidsofthegroupof

propionicacidderivatives

5.1 Pharmacodynamicproperties

Ketoprofenisaderivativeofphenylpropionicacid,andbelongstothenon-steroidal

anti-inflammatorygroupofdrugs.Likeallsuchsubstances,itsprincipal

pharmacologicalactionsareanti-inflammatory,analgesicandantipyretic.The

mechanismofactionisrelatedtotheabilityofketoprofentointerferewiththe

synthesisofprostaglandinsfromprecursorssuchasarachidonicacid.

Ketoprofeninhibitsthe biosynthesisofPGE2andPGF2αwithoutinfluencingthe

relationshipbetweenPGE2/PGF2αandthromboxanes.Eventhoughketoprofen

inhibitscyclooxygenase,thelysosomescellmembranesarestabilizedand

bradykinineffectantagonized.

5.2 Pharmacokineticparticulars

Ketoprofenisrapidlyabsorbedafterintramuscularadministration.Maximumplasma

concentrationisreachedwithin30to60minutes.Absolutebioavailabilityafter

intramuscularadministrationincattleandpigsis90-100%,inthehorse70%.The

volumeofdistributionandclearanceareapproximately0.17L/kgand0.3L/kg

respectively.Linearkineticsprevails.

Theplasmahalf-lifeafterintramuscularadministrationis2to3hours.Ketoprofen

binds95%toplasmaproteinsandismetabolisedbyreductiontothesecondary

alcohol.Itisexcretedrapidly;mainlyviatheurinei.e.80%ofthedoseadministered

Issued:October2012

AN:00043/2011

Page5of6

areeliminatedwithin12hours.Thereducedketoprofenmetaboliteprevailsincattle,

theglucuronidatedconjugateinhorses.

6. PHARMACEUTICALPARTICULARS

6.1 Listofexcipients

Benzylalcohol(E1519)

L-arginine

Citricacidmonohydrate(forpHadjustment)

Waterforinjections

6.2 Incompatibilities

Intheabsenceofcompatibilitystudies,thisveterinarymedicinalproductmustnotbe

mixedwithotherveterinarymedicinalproducts.

6.3 Shelflife

Shelflifeoftheveterinarymedicinalproductaspackagedforsale:30months.

Shelflifeafterfirstopeningthevial:28days.

6.4. Specialprecautionsforstorage

Keepthevialintheoutercartoninordertoprotectfromlight.

6.5 Natureandcompositionofimmediatepackaging

50mland100mlamberglassvials(TypeII)withredchlorobutylrubberstopper,

coveredwithanaluminumcap.Thevialsarepackagedsinglyincarboardcartons.

Notallpacksizesmaybemarketed.

6.6 Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

CP-PharmaGmbH

Ostlandring13

31303Burgdorf

Germany

Issued:October2012

AN:00043/2011

Page6of6

8. MARKETINGAUTHORISATIONNUMBER

Vm20916/4012

9. DATEOFFIRSTAUTHORISATION

24October2012

10. DATEOFREVISIONOFTHETEXT

October2012

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Administrationbyaveterinarysurgeonorundertheirdirectresponsibility.

Tobesuppliedonlyonveterinaryprescription.

26-11-2018

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

FDA Welcomes Grant Applications for Animal Drugs for Minor Uses and Minor Species

The U.S. Food and Drug Administration today announced an open period for applications for grants to support the development of new animal drugs intended to treat uncommon diseases (minor uses) in major species (horses, dogs, cats, cattle, pigs, turkeys and chickens) or to treat minor species.

FDA - U.S. Food and Drug Administration

31-10-2018

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Efficacy of Bergazym® P100 (endo‐1,4‐β‐xylanase) as a feed additive for chickens for fattening and weaned piglets

Published on: Tue, 30 Oct 2018 00:00:00 +0100 The product Bergazym® P100 contains a xylanase which is produced by a non‐genetically modified strain of Trichoderma reesei. The additive is available in a coated granular form and it is intended to be used as a zootechnical additive (functional group: digestibility enhancers) for chickens for fattening, and weaned piglets at the dose of 1,500 EPU/kg feed. The production strain and the additive were fully characterised in a previous assessment of the Panel o...

Europe - EFSA - European Food Safety Authority Publications

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

There are no news related to this product.